Japanese‐originated pharmaceutical products in the United States from 1960 to 1989: An assessment of innovation

  title={Japanese‐originated pharmaceutical products in the United States from 1960 to 1989: An assessment of innovation},
  author={Elizabeth Hawkins and Machael R. Reich},
  journal={Clinical Pharmacology \& Therapeutics},
Clinical Pharmacology and Therapeutics(1992) 51, 1–11; doi:10.1038/clpt.1992.1 

Topics from this paper

Innovation management of Japanese pharmaceutical companies: the case of an antibiotic developed by Takeda
  • T. Hara
  • Business, Computer Science
    Int. J. Technol. Manag.
  • 2005
A well-defined typology of drug innovation is suggested to address the problem of most new drugs developed by Japanese companies are imitative and lack appeal in overseas markets and should not underestimate the strategic value of modification-based innovation.
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective
The therapeutic classes most commonly associated with safety discontinuations were the nonsteroidal anti‐inflammatory drugs, vasodilators, and antidepressants, and U.S. companies or their foreign subsidiaries were involved as originators (patent‐holders and/or developers) of approximately 40% of the drugs discontinued for safety reasons.
New chemical entity output of the international pharmaceutical industry from 1970 to 1992
Although the European marketing companies dominate in total numbers first marketed over this period, there has been a significant decline in their annual output and the Japanese companies have shown a significant increase in the number of new compounds marketed annually.
American and Japanese Drug Distribution and Information Systems in 1994 and a Proposed System for Improved Pharmaceutical Care
Drug distribution environments were reported in the United States and Japan. It was observed that both countries are readily adjusting to rapidly changing drug distribution environments. In the
Technological change in the pharmaceutical industry in Japan and the United Kingdom
This thesis explores the process of technological change in the pharmaceutical industry. Although pharmaceuticals are crucial in modern society, the shaping process of this technology is not fully
Peripheral Opioid Modulation of Visceral Pain a
Understanding visceral pain mechanisms and its modulation is important to developing improved strategies for pain control, including pain arising from the viscera.
Influences on R&D growth among Japanese pharmaceutical firms, 1975–1990
Abstract In this paper, we study changes in R&D expenditure of Japanese pharmaceutical manufacturers between 1975 and 1990. The analysis contributes to our understanding of firms' R&D strategy as a
Facets of biodiversity: a contemplative paradigm on ecosystem services
  • H. Soni
  • Biodiversity International Journal
  • 2019
There are different meanings of the term “Biodiversity”. The 1992 United Nations Earth Summit characterized “Natural Diversity” as “the fluctuation among living beings from all sources, including,
l?HARMACOEPIDEMIOLOGY AND DRUG UTILIZATION clations in the United States, through 1993: regulatory perspective
  • 2004


Biotechnology in pharmaceuticals: the Japanese challenge.
Strategies used by the United States and Japan to incorporate biotechnology into their pharmaceutical industries are examined and compared.
The other Drug War: U.S.-Japan Trade in Pharmaceuticals
The Japanese pharmaceutical market is the second largest in the world, worth about $26 billion in 1985. The industry is one of the few high-technology areas in which the United States still maintains
Innovation and Discovery in the Ethical Pharmaceutical Industry
In this chapter, we focus attention on the process of innovation and discovery in one of the most dynamic and research-intensive industries in the American economy—the ethical drug industry. A
The Measurement of Pharmaceutical Innovation
The need for measures of innovation is now becoming increasingly important, however, as questions such as the rate of pharmaceutical innovation declining are addressed.
The Measurement of Therapeutic Value
This paper discusses three approaches to the evaluation of the therapeutic value or significance of individual drugs and their implications for the time it takes for it to be reviewed and, where applicable, approved for the market.
Why the Japanese Don't Export More Pharmaceuticals: Health Policy as Industrial Policy
Japan has the second largest single-county market for pharmaceutical products in the world but is one of the lowest exporters among the major producer countries, with only about 3% of total
The Growth of Japanese Science and Technology
These indicators characterize Japan as a technological powerhouse, with highly innovative technology, and an expanding but far less powerful scientific position.
Created in Japan: From Imitators to World-Class Innovators
Contents: The Managerial Imperitive; The Sociocultural Challenges; The Creativity Paradox; The Technological Race; Conclusion. In this warning to U.S. business and policymakers, Tatsuno debunks the
Japan Economic Institute Report No 6A
  • 1990
Pryor drug price bill outlined
  • Scrip April
  • 1990